ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1530

The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus

Guillermo Pons-Estel1, Rosana Quintana1, Romina Nieto1, Hermine Brunner2, Marina Scolnik3, Carmen Funes Soaje4, Paula Alba5, Veronica Saurit6, Mercedes Garcia7, GUILLERMO ARIEL BERBOTTO8, Inés Verónica Bellomio9, Mario Eduardo Kerzberg10, Graciela Gomez11, Cecilia Pisoni12, Vicente Juarez13, Ana Malvar14, Nélzio Silva15, ODIRLEI MONTICIELO16, Henrique Mariz17, Francinne Ribeiro18, Eduardo Borba19, Eloisa Bonfa19, Edgard Torres dos Reis-Neto20, Iris Guerra Herrera21, Maria Loreto Massardo22, Gustavo Aroca-Martínez23, Lorena Gómez Escorcia24, Carlos Alberto Cañas25, Gerardo Quintana-Lopez26, Carlos Toro-Gutierrez27, Mario Moreno Alvarez28, MIGUEL SAAVEDRA29, Margarita Portela Hernández30, Hilda Fragoso-Loyo31, Luis H Silveira32, Ignacio García-De la Torre33, Carlos Abud-Mendoza34, Jorge Antonio Esquivel Valerio35, Maria Isabel Acosta36, Astrid Paats37, Claudia S. Mora-Trujillo38, Manuel Ugarte-Gil39, Armando Calvo40, Roberto Muñoz-Louis41, Martin Rebella42, Alvaro Danza43, Federico Zazzetti44, Ashley Orillion45, Urbano Sbarigia46 and Bernardo A. Pons-Estel47, 1Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, 4Hospital Italiano de Córdoba, Córdoba, Argentina, Cordoba, Argentina, 5Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Cordoba, Argentina, 6Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, 7Hospital Interzonal General de Agudos “General San Martín” de la plata, La Plata, Argentina, 8Sanatorio Británico, Rosario, Argentina, ROSARIO, Argentina, 9Hospital Padilla, Tucumán, Argentina, San Miguel de Tucumán, Argentina, 10Hospital J.M Ramos Mejía, Buenos Aires, Argentina, CABA, Argentina, 11Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, 12CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, 13Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, 14Organización Médica de Investigación, Buenos Aires, Argentina, 15Hospital das Clinicas da Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, 16Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, 17Universidad Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, 18Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio De Janeiro, Rio de Janeiro, Brazil, 19Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 20Universidad Federal São Paulo, São Paulo, Brazil, São Paulo, Brazil, 21Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, 22Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, 23Clínica de la Costa y Universidad Simón Bolívar, Barranquilla, Colombia, barranquilla, Colombia, 24Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, 25Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, 26Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, 27Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, 28Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, 29Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, MEXICO, Mexico, 30Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, 31Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 32Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, 33Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Jalisco, Mexico, 34Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, San Luis Potosí, Mexico, 35Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, 36Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asuncion, Paraguay, 37Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, 38Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, 39Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, 40Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, 41Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, 42Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, 43Médica Uruguaya, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, 44Johnson & Johnson, Horsham, PA, USA, Ambler, PA, 45Johnson & Johnson, Spring House, PA, USA, Spring House, PA, 46Johnson & Johnson, Beerse, Belgium, 47Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina

Meeting: ACR Convergence 2025

Keywords: Lupus nephritis, Renal, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1517–1552) Systemic Lupus Erythematosus – Treatment Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Effective, non-invasive disease activity and treatment response assessments are needed for patients with systemic lupus erythematosus (SLE), especially if associated with kidney disease, i.e. lupus nephritis (LN). The treatment goal of LN is to achieve complete renal remission (CRR). Proteinuria of >0.5 g/day can prompt a kidney biopsy to diagnose LN. The Renal Activity Index for Lupus (RAIL) measures the degree of kidney inflammation. The RAIL-score is calculated from the creatinine-adjusted RAIL biomarkers (neutrophil gelatinase-associated lipocalin [NGAL], kidney injury molecule-1 [KIM-1], monocyte chemoattractant protein-1 [MCP-1], adiponectin, hemopexin, ceruloplasmin) and higher scores indicate higher kidney inflammation.1 This study evaluated 1) the role of RAIL to distinguish CRR status and identify the cut-point for RAIL; 2) the role of RAIL in predicting change in CRR status over time.

Methods: Urine samples collected from 69 SLE adult patients with and without LN were studied longitudinally at enrollment into the GLADEL cohort (T0), at 6 months (T1) and 12 months (T2). Absolute scores and changes in RAIL-scores over time were assessed for presence of CRR status (proteinuria of < 0.5 g/day) by logistical regression models. The Youden Index optimal cut-points on the receiver operating characteristic (ROC) curves were calculated.

Results: For 186 visits from 51 (74%; 91% female) patients with LN and 18 (26%) patients without LN diagnosis, patient characteristics and disease courses are shown in Table 1. RAIL-scores were correlated with renal-SLEDAI (r=0.46; p< 0.0001) and proteinuria (r=0.37; p=0.002). Considering all visits (CRR present/absent=146/40), mean (SD) RAIL-scores with CRR-status were 1.17 (1.53) lower than without CRR (p=0.023; area under the ROC curve =0.73), as shown in Figure 1, RAIL scores of no more than 3.4 identified CRR-status with 78% specificity (Positive Predictive Value [PPV]=0.77, sensitivity=62). Patients who newly achieved CRR-status at the next visit had a mean (SD) RAIL-score decrease of 1.0 (1.524) since the last visit (Percentage Variance Value [PVV]=82%, p=0.0024) and a further decrease of >0.57 of achieving CRR at the next visit.

Conclusion: RAIL-scores are significantly lower with CRR-status in LN and decreases of 1.0 between visits >0.57 or larger may predict future CRR achievement.

Supporting image 1Table 1. Patient characteristics & RAIL-scores over time

Supporting image 2Figure 1. ROC curve for model


Disclosures: G. Pons-Estel: AstraZeneca, 1, 6, GlaxoSmithKlein(GSK), 1, 6, Janssen, 1, 6; R. Quintana: None; R. Nieto: None; H. Brunner: AbbVie, 2, AstraZeneca-Medimmune, 2, Biogen, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, EMD Serono, 2, F. Hoffmann-La Roche, 2, Genentech, 5, GlaxoSmithKline, 2, Merck, 2, Novartis, 2, Pfizer, 2, 5, Sanofi, 2, UCB, 2; M. Scolnik: AstraZeneca, 2, 5, 6, GSK, 1, 5, 6, Janssen, 1, 5, 6, Pfizer, 1, 5, 6, Roche, 1, 5, 6; C. Funes Soaje: None; P. Alba: None; V. Saurit: None; M. Garcia: None; G. BERBOTTO: None; I. Bellomio: None; M. Kerzberg: None; G. Gomez: None; C. Pisoni: None; V. Juarez: None; A. Malvar: Bristol-Myers Squibb(BMS), 2, F. Hoffman-La Roche Ltd/Genentech, Inc., 2, GlaxoSmithKline (GSK), 2, Kezar, 2, Novartis, 2, Pfizer, 2; N. Silva: None; O. MONTICIELO: None; H. Mariz: None; F. Ribeiro: None; E. Borba: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (303378/2022-0), 5, GlaxoSmithKlein(GSK), 5; E. Bonfa: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) #305242/2019-9, 5, Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP) (2022/12925-8), 5, GlaxoSmithKlein(GSK), 5; E. Torres dos Reis-Neto: None; I. Guerra Herrera: None; M. Massardo: None; G. Aroca-Martínez: None; L. Gómez Escorcia: None; C. Cañas: None; G. Quintana-Lopez: None; C. Toro-Gutierrez: None; M. Moreno Alvarez: None; M. SAAVEDRA: None; M. Portela Hernández: None; H. Fragoso-Loyo: None; L. Silveira: None; I. García-De la Torre: None; C. Abud-Mendoza: None; J. Esquivel Valerio: None; M. Acosta: None; A. Paats: None; C. Mora-Trujillo: None; M. Ugarte-Gil: AstraZeneca, 2, 6, Ferrer, 2, 6, GSK, 2, 6, Johnson & Johnson, 5, Novartis, 2, 6, Tecnofarma, 2, 6; A. Calvo: None; R. Muñoz-Louis: None; M. Rebella: None; A. Danza: None; F. Zazzetti: Johnson & Johnson, 3, 11; A. Orillion: Johnson & Johnson, 3, 11; U. Sbarigia: Johnson and Johnson, 11; B. Pons-Estel: AstraZeneca, 5, 6, GlaxoSmithKlein(GSK), 5, 6, Janssen, 5, 6, Novartis, 6, Roche, 5.

To cite this abstract in AMA style:

Pons-Estel G, Quintana R, Nieto R, Brunner H, Scolnik M, Funes Soaje C, Alba P, Saurit V, Garcia M, BERBOTTO G, Bellomio I, Kerzberg M, Gomez G, Pisoni C, Juarez V, Malvar A, Silva N, MONTICIELO O, Mariz H, Ribeiro F, Borba E, Bonfa E, Torres dos Reis-Neto E, Guerra Herrera I, Massardo M, Aroca-Martínez G, Gómez Escorcia L, Cañas C, Quintana-Lopez G, Toro-Gutierrez C, Moreno Alvarez M, SAAVEDRA M, Portela Hernández M, Fragoso-Loyo H, Silveira L, García-De la Torre I, Abud-Mendoza C, Esquivel Valerio J, Acosta M, Paats A, Mora-Trujillo C, Ugarte-Gil M, Calvo A, Muñoz-Louis R, Rebella M, Danza A, Zazzetti F, Orillion A, Sbarigia U, Pons-Estel B. The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/the-renal-activity-index-for-lupus-identifies-and-predicts-complete-renal-remission-or-absence-of-kidney-involvement-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-renal-activity-index-for-lupus-identifies-and-predicts-complete-renal-remission-or-absence-of-kidney-involvement-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology